Jacobio Pharmaceuticals Group Co Lt (1167)

Hong Kong
4.22
+0.20(+4.98%)
  • Volume:
    184,500
  • Bid/Ask:
    4.21/4.31
  • Day's Range:
    3.93 - 4.39

1167 Overview

Prev. Close
4.02
Day's Range
3.93-4.39
Revenue
149.81M
Open
3.93
52 wk Range
3.92-20.2
EPS
-0.39
Volume
184,500
Market Cap
3.1B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,053,664
P/E Ratio
-
Beta
1.28
1-Year Change
-78.89%
Shares Outstanding
771,462,180
Next Earnings Date
-
What is your sentiment on Jacobio Pharmaceuticals Group?
or
Vote to see community's results!

Jacobio Pharmaceuticals Group Co Lt Analysis

Jacobio Pharmaceuticals Group Co Lt Company Profile

Jacobio Pharmaceuticals Group Co Lt Company Profile

Employees
262
Market
Hong Kong

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company’s lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.

Read More

Analyst Price Target

Average14.57 (+245.28% Upside)
High19.142
Low10
Price4.22
No. of Analysts2
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyNeutralSellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell